126 related articles for article (PubMed ID: 9422478)
1. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients.
Woronoff-Lemsi MC; Arveux P; Limat S; Deconinck E; Morel P; Cahn JY
Bone Marrow Transplant; 1997 Dec; 20(11):975-82. PubMed ID: 9422478
[TBL] [Abstract][Full Text] [Related]
2. Cost analysis of the introduction of PBPC for autologous transplantation: effect of switching from bone marrow (BM) to peripheral blood progenitor cells (PBPC).
Bredeson C; Malcolm J; Davis M; Bence-Bruckler I; Kearns B; Huebsch L
Bone Marrow Transplant; 1997 Nov; 20(10):889-96. PubMed ID: 9404932
[TBL] [Abstract][Full Text] [Related]
3. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of CD34+ dose in peripheral blood progenitor cell transplantation for non-Hodgkin's lymphoma patients: a single centre study.
Limat S; Woronoff-Lemsi MC; Deconinck E; Racadot E; Jacquet M; Herve P; Cahn JY
Bone Marrow Transplant; 2000 May; 25(9):997-1002. PubMed ID: 10800070
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
[TBL] [Abstract][Full Text] [Related]
6. Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies.
Vicent MG; Madero L; Chamorro L; Madero R; Diaz MA
Haematologica; 2001 Oct; 86(10):1087-94. PubMed ID: 11602415
[TBL] [Abstract][Full Text] [Related]
7. [Economic costs of autotransplantation of hematopoietic progenitors].
de Arriba F; Heras I; del Carmen Garcia M; Moraleda JM; Funes C; Ferrer F; Vicente V
Med Clin (Barc); 1996 Mar; 106(9):329-32. PubMed ID: 8667698
[TBL] [Abstract][Full Text] [Related]
8. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation.
Bennett C; Waters T; Stinson T; Almagor O; Pavletic Z; Tarantolo S; Bishop M
Bone Marrow Transplant; 1999 Sep; 24(5):555-60. PubMed ID: 10482942
[TBL] [Abstract][Full Text] [Related]
9. [Difference in costs of autologous transplantation of peripheral and bone marrow hematopoietic stem cells. A retrospective analysis over 1 year of transplantation in lymphoma, Hodgkin's disease and myeloma in a Center].
Rio B; Marjanovic Z; Belhocine R; Vekhoff A; Andrieu V; Klaren J; Boccaccio C; Delmer A; Ajchenbaum-Cymbalista F; Hunault M; Bazarbachi A; Lévy V; Andreu G; Zittoun R
Ann Med Interne (Paris); 1996; 147(5):313-9. PubMed ID: 9033732
[TBL] [Abstract][Full Text] [Related]
10. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma.
Messori A; Bonistalli L; Costantini M; Alterini R
Bone Marrow Transplant; 1997 Feb; 19(3):275-81. PubMed ID: 9028558
[TBL] [Abstract][Full Text] [Related]
12. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V
Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723
[TBL] [Abstract][Full Text] [Related]
13. Combined bone marrow and peripheral blood progenitor cell autografts for patients with poor mobilization.
Sinitsyn Y; Malone A; Mandeli J; Grosskreutz C; Osman K; Scigliano E; Shi P; Isola L
Cytotherapy; 2009; 11(4):457-63. PubMed ID: 19499401
[TBL] [Abstract][Full Text] [Related]
14. Costs of high-dose salvage therapy and blood stem cell transplantation for resistant-relapsed malignant lymphomas in a southern Italian hospital.
Mazza P; Secondo E; Palazzo G; Amurri B; Manna N; Miloro G; Moscogiuri R
Haematologica; 1999 Feb; 84(2):142-9. PubMed ID: 10091413
[TBL] [Abstract][Full Text] [Related]
15. Costs of high-dose chemotherapy and peripheral blood progenitor cell autograft for breast cancer.
De Rosa L; Lalle M; Pandolfi A; Pescador L
Bone Marrow Transplant; 2001 May; 27(10):1031-5. PubMed ID: 11438817
[TBL] [Abstract][Full Text] [Related]
16. Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma.
van Agthoven M; Kramer MH; Sonneveld P; van der Hem KG; Huijgens PC; Wijermans PW; Kluin-Nelemans HC; Schaafsma MR; Biesma DH; Mattijssen V; Uyl-de Groot CA; Hagenbeek A
Haematologica; 2005 Oct; 90(10):1422-32. PubMed ID: 16219580
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
Callera F; Cavenaghi L; de Melo CM
Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
[TBL] [Abstract][Full Text] [Related]
18. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
[TBL] [Abstract][Full Text] [Related]
19. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
[TBL] [Abstract][Full Text] [Related]
20. [Economic study of the cost of peripheral blood hematopoietic precursor autotransplantation compared with bone marrow transplantation].
Juliá A; Bueno J; Gadea N; Massuet L; del Baño C
Med Clin (Barc); 1995 Jun; 105(4):131-5. PubMed ID: 7623504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
